CVC Explores $2B Sale of Dr. Teal’s Parent Arthea

Private equity firm CVC Capital Partners is exploring a sale of personal care platform Arthea, formerly known as PDC Brands and parent to Dr. Teal's, in a transaction that could value the company at approximately $2 billion, according to an Investing.com report.

Talks regarding the potential divestiture are at an early stage, and CVC has enlisted investment banks Moelis & Company and William Blair & Company to advise on the process. The deliberations follow a rebranding period for the consumer products manufacturer and highlight private equity interest in beauty and wellness assets.

"Buyout firm CVC is in the early stages of exploring a sale of personal care platform Arthea that could value the company at approximately $2 billion," according to sources cited by Investing.com.

Portfolio and Rebranding History

The company, historically operating as Parfums de Coeur, changed its corporate moniker to PDC Brands before undergoing another name change last month to Arthea, drawing inspiration from the words art and healing. Alongside the rebranding, the consumer platform introduced a new body care line called Sunryz targeted specifically at tweens.

Arthea's product portfolio spans several mass-market beauty and wellness categories:

• Dr. Teal's: Epsom salt baths, soaks, and personal care items.
• Bodycology: Fragrance mists and moisturizing body creams.
• Body Fantasies and BOD Man: Mass-market body sprays and deodorants.
• Cantu: Specialized hair care products formulated for textured and curly hair.

Prior Investment and Valuation Trajectory

CVC acquired the platform in 2017 from private equity firm Yellow Wood Partners for $1.43 billion. A successful transaction at the targeted $2 billion valuation would represent an appreciation over the holding period, reflecting steady cash flows and brand expansions in the mass-market personal care sector.

Consumer product transactions of this scale frequently attract interest from larger multi-category conglomerates and other private equity sponsors seeking established shelf space in drugstores, mass merchandisers, and supermarket chains where brands like Dr. Teal's and Cantu maintain widespread distribution.